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Abstract
We examined the associations between adiponectin or leptin and serum ICAM-1 levels in seventy-six hypercholesterolemic patients (mean age
59 yrs, 25 males and 51 females, LDL-cholesterol>=130mg/dL at screening). Blood lipid profiles and HOMA-IR derived from fasting glucose and 
insulin concentrations were determined. Serum levels of adiponectin, leptin and ICAM-1 were analyzed using ELISA. The results showed that serum
levels of leptin were positively associated with serum levels of ICAM-1 independent of age, sex and BMI (r =0.392, p<0.001). Serum levels of
adiponectin were negatively associated with serum levels of ICAM-1 independent of age, sex and BMI (r =-0.343, p<0.005). Stepwise multiple
linear regression analysis showed that serum leptin was an independent factor to be associated with serum ICAM-1 levels after adjusting for age,
sex, BMI, alcohol intake, smoking status, blood lipids such as total cholesterol, triglyceride, HDL cholesterol and LDL cholesterol and HOMA-IR
(p<0.001). With respect to adiponectin, its association with serum ICAM-1 was attenuated but still significant when further adjustments were made
for age, sex, BMI, alcohol intake, smoking status, blood lipids such as total cholesterol, triglyceride, HDL cholesterol and LDL cholesterol and
HOMA-IR (p<0.005). In conclusion, this study suggests that adiponectin and leptin are associated with endothelial derived inflammation.
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Introduction*
Endothelial dysfunction is a collective term that incorporates 
a number of changes that the endothelium undergoes during 
atherogenesis, i.e. loss of anticoagulant properties, increased 
expression of cellular adhesion molecules and increased vascular 
tone due to loss of bioavailability of vasodilatory endothelial 
nitric oxide (Cines et al., 1998; van Haelst et al., 2003). In 
particular, current evidence supports a central role for inflam-
mation in all phases of the atherosclerotic process. Inflammatory 
processes promote the leukocytes penetrate into the intima and 
in the arterial wall in early stage. Through the processes, the 
blood-derived inflammatory cells participate in and perpetuate 
a local inflammatory response and also contribute decisively to 
precipitating acute thrombotic complications of atheroma (Libby 
et al., 2002; Libby, 2002).
The endothelial intercellular adhesion molecule-1 (ICAM-1), 
a member of the immunoglobulin superfamily of cellular adhe-
sion molecules, plays an important role in the initiation of the 
inflammatory process (Hopkins et al., 2004). ICAM-1 interacts 
with adhesion molecules on leukocytes as a first step toward 
migration of the leukocytes into the arterial intima; thus, ICAM-1 
plays a key role in the recruitment of immune cells during the 
development of atherosclerotic plaque (Kevil et al., 2001).
It has been reported on the involvement of adipokines, which 
are proteins produced mainly by adipocytes, in proatherosclerotic 
process, linking obesity with obesity associated complications 
(Ahima, 2001; Chandran et al., 2003). Adiponectin, one of the 
most abundant adipose tissue-specific adipokines, is reduced in 
obesity (Berg et al., 2001; Okamoto et al., 2002) and metabolic 
syndrome (Hu et al., 1996). Furthermore, adiponectin attenuates 
the endothelial inflammatory response in vitro, and its con-
centration is decreased in patients with coronary artery disease 
(Yamauchi et al., 2003). Adiponectin has been found to inhibit 
the expression of the adhesion molecules, such as vascular cell 
adhesion molecule-1 (VCAM-1), E-selectin and ICAM-1. 
Therefore, it interferes with monocyte adherence to endothelial 
cells and their subsequent migration to the subendothelial space, 
one of the initial events in the development of atherosclerosis 
(Ouchi et al., 1999). Leptin is predominantly expressed by 
adipocytes, and its plasma levels correlated well with the body 
fat mass (Peelman et al., 2004), fat accumulation, and insulin 
resistance (de Courten et al., 1997; Zimmet et al., 1996). Leptin 
possesses procoagulant and antifibrinolytic properties, and it 
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Table 1. Characteristics of hypercholesterolemic subjects
n = 76
Age (years) 59.3 ± 9.3
Body mass index (kg/m2) 24.5 ± 2.9
Triglyceride (mg/dL) 172.1 ± 83.2
Total cholesterol (mg/dL) 234.8 ± 27.9
LDL-cholesterol (mg/dL) 149.4 ± 21.5
HDL-cholesterol (mg/dL)  42.4 ± 11.6
Fasting glucose (mg/dL) 86.1 ± 8.7
Fasting insulin (μIU/ml)  8.3 ± 4.1
HOMA-IR index  1.8 ± 0.9
Leptin (ng/mL)  3.7 ± 3.6
Adiponectin (μg/mL)  5.9 ± 3.9
ICAM-1(ng/mL)  310.9 ± 149.2
Means ± S.D.
promotes thrombus and atheroma formation, probably through 
the leptin receptors by promoting vascular inflammation, 
proliferation and calcification (Kougias et al., 2005).
It has been reported that decreased serum adiponectin and 
increased leptin levels are found in subjects with familial 
combined hyperlipidemia characterized by increased levels of 
total cholesterol, triglycerides and/or apolipoprotein B (van der 
Vleuten et al., 2005; van der Vleuten et al., 2006). Levels of 
ICAM-1 were significantly increased in hypercholesterolemic 
patients (Hackman et al., 1996). However information on 
associations among adipokines and endothelial function as 
expressed as ICAM-1 is still limited in hypercholesterolemic 
subjects. Therefore, the purpose of this study was to investigate 
relationship between adiponectin or leptin and serum ICAM-1 
levels in hypercholesterolemic patients.
Subjects and Methods
Subjects
Seventy-six hypercholesterolemic patients (20-75 years old, 25 
males and 51 females; low-density lipoprotein cholesterol 
[LDL-C] ≥130mg/dL at screening) participated in the present 
study. Subjects who were taking hypolipidemic medication, 
antioxidative vitamins, or who had been diagnosed with type 2 
diabetes mellitus, thyroid disorders, liver or renal dysfunction 
were excluded. Body weight and height were measured and BMI 
was calculated. Venous blood samples were collected from the 
forearm in EDTA-treated and plain tubes after a fasting period. 
The tubes were immediately covered with aluminum foil and 
placed on ice until they arrived at the analytical laboratory, where 
they were stored at -70℃. All patients gave written informed 
consent, and the institutional review board at the Yonsei 
University Medical Center approved the study protocol. We 
assessed cigarette smoking history using questions about current 
or past use of cigarettes and ex-smoker who reported quitting 
smoking 1 y before the start of study. Questions about alcohol 
intake assessed the frequency of drinking per week and the 
amount of alcohol consumed.
Serum lipid profiles 
Serum cholesterol, LDL-C, and high-density lipoprotein 
cholesterol (HDL-C) were measured with commercially available 
kits (Choongwae, Seoul, Korea) by enzymatic methods. Serum 
triglyceride levels were analyzed using a total glycerol test kit 
(Roche, Basel, Switzerland). All determinants were done on a 
Hitachi 747 autoanalyzer (Hitachi, Tokyo, Japan).
Serum glucose, insulin, and homeostasis model assessment 
Fasting serum glucose concentrations were measured by the 
glucose oxidase method using a Beckman Glucose Analyzer 
(Beckman Instruments, Irvine, CA). Insulin was measured by 
radioimmunoassay with commercial kits from Immuno Nucleo 
(Stillwater, MN). We calculated the homeostasis model asses-
sment of insulin resistance (HOMA-IR) using the equation: 
HOMA-IR = fasting insulin (µU/mL) × glucose (mmol/L)/22.5 
(Mathews et al., 1985).
Serum sICAM-1, adiponectin and leptin 
Serum sICAM-1 (Human ICAM-1, R&D Systems, Min-
neapolis, MN) and adiponectin levels (Human Adiponectin 
Enzyme-Linked Immunosorbent Assay Kit, Biovendor, BRNO, 
Czech Republic) were measured by enzyme immunoassay. The 
resultant color reaction was read with a Victor2 measuring A450. 
A Packard Cobra II 5005 γ-Counter with Human Leptin 
Radioimmunoassay Kit (Linco, Research, St Charles, MO) was 
used to measure leptin concentrations. 
Statistical analysis
The SPSS 12.0 software package (SPSS, Chicago, IL) was used 
for statistical analysis. Data were presented as mean ± SD. Each 
variable was examined for normal distribution, and abnormally 
distributed variables were log-transformed. We used the Pearson 
correlation coefficient to evaluate relationships between varia-
bles. A stepwise multiple regression analysis was used to identify 
the factors which were associated with serum ICAM-1 levels. 
P values of less than .05 were considered statistically significant.
Results
Mean age and body mass index (BMI) of total subjects were 
59.3 ± 9.3 years and 24.5 ± 2.9 kg/m2, respectively (Male: Female 
= 25:51). 
Table 1 presented the serum concentrations of serum lipids, 
leptin, adiponectin and ICAM-1 and calculated HOMA-IR of 
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Fig. 1. Correlations between leptin or adiponectin and Serum ICAM-1 levels of the subjects
Table 2. Stepwise multiple regression analyses to identify factors influencing 
serum ICAM-1
Dependent
variable Model
Independent
Variable
Adjusted p-value R p-value
β-coefficients
ICAM-1
1 step Leptin 0.375 < 0.001 0.375 < 0.001
2 step Leptin 0.417 < 0.001
0.535 < 0.001
Age 0.315 0.006
Included independent variables: age, gender, BMI, alcohol intake, smoking status, 
blood lipids, HOMA-R, adiponectin and leptin.
total subjects. We examined correlations between serum ICAM-1 
and two adipokine levels such as leptin and adiponectin. The 
results showed that serum levels of leptin were positively 
associated with serum levels of ICAM-1 independent of age, sex 
and BMI (r = 0.392, p<0.001, Fig. 1). Serum levels of adiponectin 
were negatively associated with serum levels of ICAM-1 
independent of age, sex and BMI (r = -0.343, p<0.005, Fig. 1).
Stepwise multiple linear regression analysis was performed to 
examine the associations between levels of 2 adipokines and 
levels of ICAM-1. Serum leptin was an independent factor to 
be associated with serum ICAM-1 levels after adjusting for age, 
sex, BMI, alcohol intake, smoking status, blood lipids such as 
total cholesterol, triglyceride, HDL cholesterol and LDL choles-
terol and HOMA-IR (p<0.001). With respect to adiponectin, its 
association with serum ICAM-1 was attenuated but still signi-
ficant when further adjustments were made for age, sex, BMI, 
alcohol intake, smoking status, blood lipids such as total choles-
terol, triglyceride, HDL cholesterol and LDL cholesterol and 
HOMA-IR (p<0.005). However, the association of the levels of 
adiponectin with the levels of ICAM-1 was no longer significant 
in a model including levels of leptin (Table 2).
Discussion
Circulating soluble ICAM-1 (sICAM-1) is a biochemical 
marker associated with atherosclerotic progression and other 
inflammatory disease processes (van de Stolpe & van der Saag., 
1996; Witkowska, 2005). Serum sICAM-1 levels have been 
found to be significantly elevated in patients with multiple risk 
factors for atherosclerosis, with coronary heart disease and 
myocardial infarction compared with matched control 
(Glowinska et al., 2005; Ikata et al., 2000; Zeitler et al., 1997). 
Obesity is known to be one of the major risk factors for 
atherosclerosis. The obese state is characterized by what has been 
called low-grade systemic inflammation (Berg & Scherer, 2005). 
Compared with lean subjects, inflammatory markers, such as 
C-reactive protein (CRP), IL-6 and sICAM-1 are increased in 
obese individuals (Fantuzzi, 2005; Ziccardi et al., 2002). 
Adipokines, such as adiponectin and leptin, of which secretory 
levels in blood are altered with excess adiposity, profoundly 
influence inflammatory process and thus may play important role 
in the atherosclerotic process (Lau, 2005; Lyon, 2003).
In the present study, we investigated the relationship between 
adiponectin or leptin and serum ICAM-1 levels in hyper-
cholesterolemic patients. The concentrations of adiponectin and 
ICAM-1 in our subjects were 5.9 ± 3.9 ng/mL and 310.9 ± 149.2 
ng/mL, respectively, which showed similar levels of 6.0 ± 1.4 
ng/mL (Sonmez et al., 2006) and 314 ± 36 ng/mL (Hackman 
et al., 1996) in patients with dyslipidemia. We observed that 
serum adiponectin was negatively correlated with serum ICAM-1 
level, whereas serum leptin showed significantly positive relation 
with serum ICAM-1 in hypercholesterolemic patients. These 
results are consistent with the previous human studies demon-
strating the negative correlation between plasma adiponectin and 
ICAM-1 and positive correlation between plasma leptin and 
ICAM-1 (Kent et al., 2004). Karaduman et al. (2006) reported 
that ICAM-1 levels were negatively correlated with adiponectin 
levels from human coronary atherosclerotic plaque. 
Several in vitro and animal studies have indicated that 
adiponectin possesses anti-inflammatory properties. Physiologi-
cal concentration of adiponectin reduced monocyte cell adhesion 
suppressing by TNF-α or resistin mediated mRNA expressions 
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of ICAM-1 in human aortic vascular endothelial cells (Kawanami 
et al., 2004; Ouchi, 1999). Over-expression of adiponectin 
attenuated endothelial inflammatory response, in part by down- 
regulating adhesion molecules in apolipoprotein E-deficient mice 
(Okamoto et al., 2002). From the literature, it is well known 
that leptin is an independent risk factor for cardiovascular 
diseases (CVD). Plasma leptin levels positively predicted 
cardiovascular events even after adjusting for traditional risk 
factor, BMI, and plasma C-reactive peptide (CRP) levels in a 
case-control study nested within the WOSCOPS clinical trial 
(Wallace et al., 2001). Van der Vleuten et al. (2005) reported 
that increased leptin levels were associated with an increased 
risk for CVD both in familial combined hyperlipidemia (FCH) 
patients and in healthy controls, independent of BMI, insulin 
resistance and gender.
We demonstrated in the present study that serum leptin was 
an independent factor to determine serum ICAM-1 levels after 
adjusting for age, sex, BMI, alcohol intake, smoking status, blood 
lipids such as total cholesterol, triglyceride, HDL cholesterol and 
LDL cholesterol and HOMA-IR. The study in Mexican 
Americans which reported the negative correlation between 
ICAM-1 and leptin is only one that can support our findings 
(Kent et al., 2004). To our knowledge no in vitro or in vivo 
studies have confirmed the direct effects of leptin on cell 
adhesion molecule expression. Skilton et al. (2005) have found 
that increasing concentrations of leptin did not change either the 
expression of cellular adhesion molecule (VCAM-1, ICAM-1 and 
E-selectin) or the degree of monocyte adhesion to endothelial 
cells. Increasing leptin levels in lean and obese men over 3 d 
did not alter serum ICAM-1. Moreover, recombinant methionyl 
human leptin administration in obese subjects with type 2 
diabetes mellitus, for 4 or 16 wk, resulting in high pharmacologic 
leptin levels, did not activate ICAM-1 (Chan et al., 2005). The 
significant negative relation between leptin and ICAM-1 from 
our study could not be possibly explained by limited in vitro 
and human administration studies. Therefore, the disagreement 
in relation between leptin and ICAM-1 is needed to be further 
investigated. 
This study suggests that adiponectin and leptin might be 
associated with endothelial function. Our results provide an 
understanding linking obesity, adipokines and endothelial 
function which lead to atherosclerotic process and cardiovascular 
disease in hypercholesterolemic patients.
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